

## **dorzolamide 2% preservative-free unit dose eye drops (Trusopt<sup>®</sup>)**

**Merck Sharp & Dohme**

**(No. 238/06)**

### Product Update

10 February 2006 (*Issued May 2006*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises the NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**dorzolamide 2% preservative-free unit-dose eye drops (Trusopt<sup>®</sup>)** are accepted for restricted use in NHS Scotland for the treatment of elevated intra-ocular pressure in ocular hypertension, open-angle glaucoma and pseudo-exfoliative glaucoma. They are licensed as adjunctive therapy to beta-blockers and as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contra-indicated.

This preparation is substantially more expensive than the equivalent multi-dose eye drop preparation and should be restricted to use in patients for whom dorzolamide is appropriate and who have proven sensitivity to the preservative benzalkonium chloride.

#### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 13 January 2006.*

**Chairman,  
Scottish Medicines Consortium**